Blefamide

Quick links to important sections

Blefamide

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Blefamide

Property Description
Active Ingredients Prednisolone Acetate, Sulfacetamide Sodium
Form Ophthalmic Suspension (Eye Drops)
Pharmacological Class Corticosteroid and Sulfonamide Antibiotic Combination
General Purpose Manage ocular inflammation and bacterial proliferation
Origin Synthetic

What is Blefamide and How is it Classified?

Blefamide is a combination drug strictly classified as a Topical Ophthalmic Agent, consisting of two distinct active ingredients for simultaneous effect. The formulation pairs the synthetic corticosteroid Prednisolone Acetate and the sulfonamide antibiotic Sulfacetamide Sodium. This dual composition places it within the high-level pharmacological class of a Corticosteroid and Anti-infective Combination. Unlike treatments featuring a single therapeutic component, Blefamide is engineered to deliver dual action directly to the surface structures of the eye, integrating both an anti-inflammatory agent and an antimicrobial agent into one preparation. This combined approach is clinically recognized for addressing the complexity of eye conditions involving both irritation and potential bacterial involvement.

The Composition and Form of Blefamide

The medicine is supplied as an Ophthalmic Suspension, a liquid preparation for administration as Eye Drops directly onto the eye surface. Its physical composition involves the two active ingredients—Prednisolone Acetate and Sulfacetamide Sodium—maintained within an aqueous ophthalmic vehicle. The utilization of Prednisolone Acetate in suspension form is a distinguishing characteristic, often necessary for adequate ocular delivery due to the ingredient's low solubility. This topical ophthalmic route ensures the medicine acts locally where it is needed, maximizing therapeutic concentration on the eye surface while limiting systemic distribution, a design feature specific to its use in the delicate anterior segment of the eye.

What is the General Purpose of Blefamide?

The overall therapeutic purpose of Blefamide is to provide simultaneous management of swelling and bacterial growth in ocular conditions where both inflammation and potential microbial presence are factors. The Prednisolone Acetate component functions to mitigate the painful symptoms of swelling and redness through suppression of inflammation, while the Sulfacetamide Sodium component contributes a bacteriostatic action, working to inhibit the growth and propagation of specific susceptible bacteria. The combination aims to offer prompt relief from irritation and support foundational control against bacterial proliferation, making it a common choice when addressing an inflamed eye surface where bacterial involvement is suspected.

Regulatory References

  1. MedlinePlus Ophthalmic Agents

What side effects are possible with Blefamide?

Possible Side Effects and Safety Information

The safety profile for this ophthalmic suspension is officially classified based on the effects of both the corticosteroid (Prednisolone Acetate) and the antibiotic (Sulfacetamide Sodium) components, with reactions grouped by frequency and affected physiological system.

Frequency and Organ System Classification

Adverse reactions most frequently reported are localized to the eye and surrounding structures, commonly including transient stinging, burning, irritation, and foreign body sensation upon instillation. These effects are generally associated with the initiation of administration. Less common reactions involve ocular hyperemia or allergic sensitization.

Serious and Duration-Related Safety Concerns

The most significant safety considerations are related to prolonged use, which is typically defined as exceeding ten days. The corticosteroid component is associated with a risk of increased Intraocular Pressure (IOP), which may lead to glaucoma and potential optic nerve damage. Long-term use is also linked to the formation of posterior subcapsular cataracts. Additionally, the sulfonamide component carries a rare but serious systemic risk of severe hypersensitivity reactions, such as Stevens-Johnson syndrome.

Regulatory Restrictions and Specific Populations

Official labeling includes explicit restrictions on use. The medicine is contraindicated in individuals with a known hypersensitivity to any sulfonamide derivative. Due to the immunosuppressive effect of the corticosteroid, use is also restricted in cases of most active viral diseases (including Herpes Simplex) or fungal diseases of the eye, as this may mask or enhance the infection. Safety and effectiveness are not established in children younger than two months of age.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Blefamide Ophthalmic Suspension defines acute overdose risk primarily in the context of accidental oral ingestion of the concentrated product, which can lead to systemic toxicity from the Sulfacetamide Sodium component. Topical use is not ordinarily expected to cause acute systemic problems.

Documented Overdose Manifestations and Outcomes

Overdosage via large oral exposure may result in documented manifestations such as nausea and vomiting. More serious outcomes are associated with potential Acute Sulfonamide Nephrotoxicity. This severe toxicity includes the documented risks of renal shutdown, crystalluria, and hematuria, stemming from the precipitation of sulfa crystals in the urinary tract.

Required Emergency Action

It is an official regulatory mandate to seek immediate medical attention or contact a regional poison control center if the medication is accidentally swallowed. Contact with a healthcare professional or hospital emergency department must be made immediately, even if there are no symptoms are present. In scenarios involving confirmed or suspected systemic overdosage, emergency treatment should be started immediately to manage documented complications. No specific antidote is officially detailed for this combination product.

Therapeutic Uses of Blefamide

What Blefamide Treats: Main Uses and Benefits

Blefamide is relevant in contexts marked by increased discomfort or tension caused by inflammatory and potentially infectious episodes. Its therapeutic relevance is within the domains of managing symptoms related to inflammatory or irritative states and addressing situations where bacterial involvement is a factor on the eye's surface.

Management of Symptoms in Inflammatory Conditions Where Bacterial Involvement is Relevant

This medication is commonly used across conditions presenting with acute episodes of inflammation, such as certain forms of blepharitis, keratitis, and in situations where a risk of bacterial ocular infection is present. The combination is applied when appropriate for steroid-responsive inflammatory ocular conditions where a corticosteroid is deemed necessary and where a risk of bacterial ocular infection exists. The key benefit supports the patient during difficult episodes by easing distress associated with both irritation and bacterial risk.

Addressing Acute Ocular Discomfort and Supporting Recovery

Blefamide is applied in addressing symptoms related to inflammatory or irritative states of the eye's anterior segment. It helps address symptom clusters that may become intense or disruptive, including acute eye pain, intense itching, and pronounced swelling or redness. This medication is also applied in scenarios where additional management of discomfort is required following physical damage, such as post-trauma management or certain postoperative care contexts. By moderating these distressing manifestations, the medication contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort.


Focus: Symptoms Related to Irritative States Blefamide is commonly used to help with acute symptomatic phases characterized by significant eye redness and swelling, providing supportive relief when these symptoms interfere with routine activities.

Regulatory References

  1. DailyMed Label for Sulfacetamide Sodium and Prednisolone Sodium Phosphate

Eligibility and Restrictions for Use

Who Can and Cannot Use Blefamide?

The eligibility for the ophthalmic combination containing Prednisolone Acetate and Sulfacetamide Sodium is strictly defined by regulatory documents, focusing on patient status and existing ocular conditions.


Absolute Contraindications

The medicine must not be used by individuals with known or suspected hypersensitivity to any component, including other sulfonamide derivatives or other corticosteroids. It is also contraindicated in the presence of most viral diseases of the eye (such as Herpes Simplex Keratitis, Vaccinia, or Varicella), as well as mycobacterial or fungal infections of the ocular structures, and acute purulent untreated eye infections.


Age-Group Eligibility and Restrictions

Use is established for adults and children aged 6 years and older. Safety and effectiveness have not been established in children younger than 6 years of age. Furthermore, no information is available regarding age-related effects in the geriatric population.


Conditional Use and Special Populations

Use requires caution in patients with glaucoma, diseases causing thinning of the cornea or sclera, and following cataract surgery. For women who are pregnant, particularly in the later stages, use requires weighing potential benefits against the risk of the sulfonamide component causing kernicterus in the neonate. During lactation, official guidance advises a decision to either discontinue nursing or discontinue the drug.

What should I know about interactions with other medicines?

The official interaction profile for Blefamide is primarily based on the Sulfacetamide Sodium component, documenting restrictions due to chemical incompatibility and pharmacodynamic effects, rather than systemic drug-drug interactions typical of oral medicines.

The regulatory documents establish two primary categories of interaction constraints. First, the product is subject to a clear chemical incompatibility, which prohibits co-administration with any preparation containing silver compounds. Second, the effectiveness of the antibacterial component is reduced by certain substances. This pharmacodynamic antagonism occurs with Para-aminobenzoic acid (PABA), a substance present in purulent exudates, and with certain local anesthetics that are PABA-esters.

Interaction Category Documented Constraint or Outcome
Incompatible Preparations Co-administration with silver preparations is prohibited due to a known chemical incompatibility.
Efficacy-Reducing Substances The antibacterial action is reduced by Para-aminobenzoic acid (PABA) and by certain local anesthetics that are PABA-esters.
Population-Specific Caution Use by pregnant women near term or nursing mothers requires specific consideration due to the risk of kernicterus in the newborn, based on the known effects of systemically absorbed sulfonamides.

This official profile does not document metabolic (CYP enzyme) or transporter-mediated interactions for the topical ophthalmic formulation. The structure emphasizes mandatory constraints against combining with chemically incompatible substances and notes population-specific cautions based on the potential for minimal systemic absorption of the sulfonamide component.

Mechanism of Action

Blefamide is a combination agent with two distinct mechanisms. Sulfacetamide, a sulfonamide antimicrobial, exerts a bacteriostatic effect via competitive antagonism of bacterial para-aminobenzoic acid (PABA). This interaction occurs at the active site of the enzyme dihydropteroate synthase, blocking the synthesis of dihydrofolic acid. This inhibition interrupts the folate metabolic pathway, which is essential for bacterial nucleic acid synthesis, thereby restricting microbial proliferation.

Prednisolone, a synthetic glucocorticoid, modulates cellular transcription in local tissues. It penetrates target cells and binds to the cytosolic glucocorticoid receptor (GR). The activated complex translocates to the nucleus where it acts as a transcription factor, primarily through transrepression. This involves binding to and inhibiting transcription factors such as NF-kappaB and AP-1. Downstream effects include reduced gene expression of pro-inflammatory mediators, including cytokines (e.g., interleukins), chemokines, and adhesion molecules. This cascade results in suppressed migration of immune cells and stabilization of capillary permeability, leading to systemic physiological modulation of the inflammatory response.

Dosage and Administration Information

Blefamide (sulfacetamide sodium and prednisolone acetate) is used via the topical ophthalmic route, applied as a liquid suspension directly into the conjunctival sac of the eye. Due to the physical nature of the suspension, the container must be shaken well before using to ensure uniform dispersion of the active components.

The standard adult dosing regimen involves the instillation of two drops into the affected eye(s). This application is scheduled intermittently, specifically every four hours during waking hours, with a final dose at bedtime. In cases where the condition is initially severe, the frequency of application may be intensified to every two hours during the first 24 to 48 hours of treatment. This precise dosage regimen applies equally to children 6 years of age and older, while the use in children younger than six years is not formally established.

The duration of use is generally short-term, limited by a restriction that not more than 20 milliliters should be prescribed initially. A key principle of management over time is the protocol to gradually decrease the frequency of application when withdrawing therapy for chronic conditions, rather than stopping abruptly. Furthermore, a crucial administration constraint is the observation of a 5-minute interval if another topical ophthalmic medication is being used simultaneously.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Blefamide

This section provides an overview of the types of research and clinical studies that have been examined concerning the use of the combination medicine (Prednisolone Acetate and Sulfacetamide Sodium) for eye conditions, according to information reviewed by health authorities.


Evidence for Steroid-Responsive Ocular Inflammation

Blefamide was studied for conditions involving the eye's front structures (anterior segment) that respond to anti-inflammatory treatment, particularly when a risk of bacterial presence was associated with the condition. Research focused on acute situations, such as certain forms of inflammation of the middle layer of the eye (anterior uveitis) and inflammation observed in post-operative ocular contexts.

These Randomized Controlled Trials (RCTs) and regulatory-cited clinical studies focused on short-term or episodic symptom patterns. Researchers examined outcomes related to specific clinical indicators of inflammation. For example, studies monitored the severity of redness and swelling, as well as objective measures like scores for anterior chamber cell and flare. The research also explored outcomes related to the stability of the patient's clinical condition or the requirement for additional intervention.


Evidence for Superficial Ocular Inflammations (Blepharitis and Conjunctivitis)

The medicine was also evaluated in research exploring its use for common surface conditions like blepharitis (eyelid inflammation) and certain types of conjunctivitis (pink eye) where both inflammation and bacterial involvement was observed in some studies. Studies focusing on these conditions are relevant in trials assessing short-term or episodic symptom patterns.

These research settings, which included comparative trials and systematic reviews, often examined patient-reported outcomes describing symptom intensity or variability. Specific outcomes studied included changes in eyelid swelling, discharge, and the severity of eye redness. The research described changes measured during the study period concerning the evolution of acute symptoms and signs.


What is Still Uncertain About the Research

The research landscape presents several areas where certainty remains low or further study is needed. A primary limitation is that sample sizes were modest and follow-up durations were limited in many acute-care trials, meaning the focus was observed in short-term changes but not long-term maintenance. Furthermore, comparative evidence is lacking in some areas. The research provides context but not individual predictions, and evidence highlights what is known — and what is still uncertain — regarding prolonged use or application in complex, chronic disease states.

Key Studies & References

  1. Labeling for Sulfacetamide Sodium and Prednisolone Sodium Phosphate Ophthalmic Suspension (DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Blefamide (FAQ)


Q: What is the main difference between Blefamide and other similar eye drops?

According to official product descriptions, Blefamide is a combination medicine. This means it contains two distinct active ingredients: a synthetic anti-inflammatory corticosteroid (prednisolone acetate) and an anti-infective sulfonamide antibiotic (sulfacetamide sodium). This formulation provides a dual action that addresses both inflammation and bacterial proliferation.


Q: How long can I continue to use Blefamide for my condition?

Blefamide is generally intended for short-term use. The initial prescription is limited to a volume of 20 milliliters or less. Official information indicates that use exceeding 10 days is considered prolonged and is associated with an increased risk of certain serious side effects, such as changes in eye pressure.


Q: Is Blefamide safe to use with artificial tears or lubricating eye drops?

When using Blefamide at the same time as any other topical eye medication, including artificial tears, official guidelines recommend observing a minimum 5-minute interval between applications. This is to ensure each medicine has enough time to be absorbed properly.


Q: What type of eye infection or inflammation is Blefamide approved to treat?

According to official labeling, Blefamide is used to treat inflammatory conditions of the anterior segment of the eye. This is specified for cases where a corticosteroid is appropriate and where there is a risk of a superficial bacterial ocular infection. Examples of conditions studied include certain forms of conjunctivitis and anterior uveitis.


Q: What is the maximum number of days Blefamide is typically prescribed for?

Official regulatory information indicates that eye drops containing the corticosteroid component should typically not be used for more than 10 days. Prolonged use beyond this time requires a healthcare professional's specific guidance and careful monitoring.


Q: What are the signs of an allergic reaction to Blefamide?

Due to the sulfonamide component, there is a risk of serious hypersensitivity reactions. Signs can include rash, hives, difficulty breathing, or swelling of the face, tongue, or throat. Regulatory information also notes that red or irritated eyes may be a sign of a reaction.


Q: What is the risk of resistance if Blefamide is used too often?

Official warnings indicate that unnecessary use or overuse of any antibiotic, including the sulfacetamide component in Blefamide, can lead to a decrease in its effectiveness. The antibiotic is only active against specific types of susceptible organisms and does not treat all infections.


Q: Does Blefamide have any systemic absorption (into the body, not just the eye)?

While the topical eye drop route limits distribution throughout the body, regulatory documents note the potential for minimal systemic absorption of the sulfonamide component. This potential is a reason why specific caution is outlined for pregnant women near term and nursing mothers.


Q: Can Blefamide cause blurred vision right after I use it?

Yes, temporary blurred or unstable vision is listed in official product information as an adverse reaction that may occur after application. Regulatory information indicates that waiting until vision clears completely before driving or operating machinery is necessary.


Q: Do I need a prescription to get Blefamide?

According to official regulatory labeling, Blefamide is classified as a human prescription drug. This means it is available only with a valid prescription from a licensed healthcare professional.


Q: What if I miss using Blefamide one time?

Consumer information outlines that if a dose is missed, it may be used as soon as it is remembered. However, if the next scheduled dose is near, the missed dose is typically skipped. Regulatory advice is against doubling the dose to catch up.


Q: Does Blefamide contain a preservative?

Regulatory patient information notes that the product may contain inactive ingredients, which can include preservatives. Preservatives like benzalkonium chloride are sometimes included in these types of eye drops.


Q: Does Blefamide interact with contact lens solutions?

Official guidance indicates that patients should consult their healthcare provider before using any new or different eye medicines or solutions. Furthermore, general patient information outlines the avoidance of wearing contact lenses unless specifically instructed to do so by a doctor.


Q: Are there different strengths or formulations of Blefamide?

According to DailyMed labeling, the ophthalmic suspension contains sulfacetamide sodium 10% and prednisolone acetate 0.2%. There is only one strength of this specific combination product listed in the US market documents.


Q: What should I do if I accidentally swallow a small amount of Blefamide?

Official regulatory information advises that the medicine may be harmful if swallowed, as it is only intended for topical use. Regulatory information directs users to call the Poison Control Center right away in the event of accidental ingestion.


Q: Does using Blefamide affect driving or operating machinery?

Yes, because the medication may cause temporary blurred or unstable vision, official warnings indicate caution should be exercised. Furthermore, official warnings state that waiting several minutes for vision to clear completely before driving or operating machinery is necessary.


Q: Can Blefamide make my eyes sensitive to light?

Increased sensitivity of the eyes to light (photophobia) is a reaction listed in the official product information. The frequency with which this side effect occurs is not currently known.


Q: Is Blefamide available in a generic version?

The chemical combination of the active ingredients, sulfacetamide sodium and prednisolone acetate ophthalmic suspension, is listed with standard drug classification codes. This suggests that generic versions of the chemical combination are available on the market.


Q: Does Blefamide cause eye discharge or crusting?

Official product information states that adverse reactions that have been reported with the use of this combination product include eye discharge or the formation of crusts around the eye.


Q: Can I wear my soft contact lenses while using Blefamide?

Official patient information outlines that wearing contact lenses should be avoided unless a patient has been specifically instructed to wear them by a healthcare professional during treatment.


Q: Is Blefamide used for prevention or only for treatment?

The drug's general purpose is to manage established ocular inflammation and bacterial proliferation. Therefore, it is primarily intended for the treatment of conditions where both inflammation and potential infection are factors.


Q: What happens if I use Blefamide after its expiration date?

Official guidance indicates that using any medication after its expiration date is typically not advised. Over time, the active ingredients may become less effective, and the risk of contamination may also increase.


Q: Is temporary vision cloudiness common after applying the drops?

Yes, temporary vision cloudiness or blurring is a known effect that may occur immediately following the application of the drops. This is often associated with the suspension form of the medicine.


Q: Can Blefamide cause a change in the color of the eye?

Official product information does not list a change in the color of the eye (known as iris color change) as a known adverse reaction associated with the use of this combination medicine.


Q: Is it safe to share Blefamide with another person?

Official patient information outlines the avoidance of sharing the bottle. Using the bottle by more than one person carries the risk of spreading infection.


Q: Why is it important not to touch the eye with the dropper tip of Blefamide?

Official guidance is provided to prevent eye injury and contamination of the medicine. This guidance outlines the importance of avoiding touching the bottle tip to the eyelids or to any other surface during application.

How should Blefamide be stored and disposed of?

How to Store and Dispose of Blefamide

Blefamide (sulfacetamide sodium and prednisolone acetate ophthalmic suspension) must be stored upright at controlled room temperature, maintaining a strict range between 15 C and 25 C (59 F and 77 F). The product must be protected from freezing and should not be stored above 25 C.

Storage Constraints and Stability

The container must be kept tightly closed when not in use. It is mandated that the ophthalmic suspension is shaken well before use and that the product is kept out of the reach of children. Once the bottle has been opened, the contents should not be used for longer than one month.

Disposal Requirements

Any unused product, or waste material, must be disposed of in accordance with local requirements. Official guidance advises against discarding medicines via household trash or wastewater unless specific local regulations permit this approach.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Blefamide found in:

A-Z Index: